Forensic Toxicology

, Volume 31, Issue 1, pp 76–85

Analysis of azepane isomers of AM-2233 and AM-1220, and detection of an inhibitor of fatty acid amide hydrolase [3′-(aminocarbonyl)(1,1′-biphenyl)-3-yl]-cyclohexylcarbamate (URB597) obtained as designer drugs in the Tokyo area

  • Jun’ichi Nakajima
  • Misako Takahashi
  • Takako Seto
  • Chieko Kanai
  • Jin Suzuki
  • Masao Yoshida
  • Nozomi Uemura
  • Tomoko Hamano
Original Article

DOI: 10.1007/s11419-012-0169-y

Cite this article as:
Nakajima, J., Takahashi, M., Seto, T. et al. Forensic Toxicol (2013) 31: 76. doi:10.1007/s11419-012-0169-y

Abstract

During our careful survey of unregulated drugs from November 2011 to January 2012 in the Tokyo area, we found two new compounds in commercial products. The first was identified as the benzoylindole (2-iodophenyl)[1-(1-methylazepan-3-yl)-1H-indol-3-yl]methanone (2), which is the azepane isomer of AM-2233 (1). Compound 2 was isolated by silica gel column chromatography, and was identified through a combination of liquid chromatography–mass spectrometry, gas chromatography–mass spectrometry, accurate mass spectrometry, and nuclear magnetic resonance spectroscopy. The second compound was identified as [3′-(aminocarbonyl)(1,1′-biphenyl)-3-yl]-cyclohexylcarbamate (URB597, 5) by comparing analytical data with that of the authentic compound. For quantitation of these three compounds, each commercial product was extracted with methanol under ultrasonication to prepare the solution for analysis by liquid chromatography with ultraviolet detection. The occurrence of compounds 1 and 2, and AM-1220 (3) and its azepane isomer (4) in 29 commercial products found in the Tokyo area are also shown in this report.

Keywords

Azepane isomers of AM-2233, AM-1220 URB597 Designer drug 

Copyright information

© Japanese Association of Forensic Toxicology and Springer Japan 2012

Authors and Affiliations

  • Jun’ichi Nakajima
    • 1
  • Misako Takahashi
    • 1
  • Takako Seto
    • 1
  • Chieko Kanai
    • 1
  • Jin Suzuki
    • 1
  • Masao Yoshida
    • 1
  • Nozomi Uemura
    • 1
  • Tomoko Hamano
    • 1
  1. 1.Division of DrugsTokyo Metropolitan Institute of Public HealthTokyoJapan